Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

Not specified

Study Completion Date

August 31, 1998

Conditions
Sarcoma, KaposiHIV Infections
Interventions
DRUG

Doxorubicin hydrochloride (liposomal)

DRUG

Filgrastim

DRUG

Bleomycin sulfate

DRUG

Vincristine sulfate

Trial Locations (17)

10021

Memorial Sloan-Kettering Cancer Ctr., New York

14215

SUNY - Buffalo, Erie County Medical Ctr., Buffalo

33136

Univ. of Miami AIDS CRS, Miami

35294

Alabama Therapeutics CRS, Birmingham

46202

Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis

60611

Northwestern University CRS, Chicago

60612

Rush Univ. Med. Ctr. ACTG CRS, Chicago

63110

Washington U CRS, St Louis

80262

University of Colorado Hospital CRS, Aurora

90033

USC CRS, Los Angeles

90095

UCLA CARE Center CRS, Los Angeles

96813

Queens Med. Ctr., Honolulu

96816

Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu

Unknown

Ucsf Aids Crs, San Francisco

Massachusetts General Hospital ACTG CRS, Boston

02118

Bmc Actg Crs, Boston

02215

Beth Israel Deaconess - East Campus A0102 CRS, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sequus Pharmaceuticals

INDUSTRY

collaborator

Amgen

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001059 - Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS | Biotech Hunter | Biotech Hunter